Dr. Sarbajit Mukherjee, MD
Claim this profileRoswell Park Cancer Institute
Studies Stomach Cancer
Studies Esophageal Cancer
13 reported clinical trials
24 drugs studied
Area of expertise
1Stomach Cancer
Stage IV
Stage III
HER2 positive
2Esophageal Cancer
Stage IV
Stage III
HER2 positive
Affiliated Hospitals
Clinical Trials Sarbajit Mukherjee, MD is currently running
Nivolumab + Standard Treatment
for Stomach and Esophageal Cancer
This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Adding nivolumab to ramucirumab and paclitaxel may work better to treat patients with advanced stomach or esophageal cancer.
Recruiting1 award Phase 2 & 320 criteria
Neratinib + TDxD
for Esophageal and Stomach Cancer
This trial is testing a combination of two drugs, Neratinib and TDxD, in patients with advanced stomach cancer that overexpresses HER2. These patients have not responded to previous treatments. The drugs work by blocking cancer growth and directly killing cancer cells.
Recruiting1 award Phase 119 criteria
More about Sarbajit Mukherjee, MD
Clinical Trial Related1 year of experience running clinical trials · Led 13 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Sarbajit Mukherjee, MD has experience with
- Nivolumab
- Pembrolizumab
- Paclitaxel
- Atezolizumab
- Oxaliplatin
- Fluorouracil
Breakdown of trials Sarbajit Mukherjee, MD has run
Stomach Cancer
Esophageal Cancer
Colorectal Cancer
Skin Cancer
Colon Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Sarbajit Mukherjee, MD specialize in?
Is Sarbajit Mukherjee, MD currently recruiting for clinical trials?
Are there any treatments that Sarbajit Mukherjee, MD has studied deeply?
What is the best way to schedule an appointment with Sarbajit Mukherjee, MD?
What is the office address of Sarbajit Mukherjee, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.